In conversation with... Arnon Kater and Sabina Kersting

from Listen to The Lancet · host The Lancet

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

Episode metadata supplied by the publisher feed · Published Dec 1, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Arnon Kater and Sabina Kersting

0:00 24:24

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet?

This episode is 24 minutes long.

When was this Listen to The Lancet episode published?

This episode was published on December 1, 2025.

Can I download this Listen to The Lancet episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!